Preclinical evaluation of lovastatin

The American Journal of Cardiology

Volumn 62, Issue 15, 1988, Pages

  MacDonald, James S ^a,b   Gerson, Ronald J ^a,b   Kornbrust, Douglas J ^a,b   Kloss, Michelle W ^a,b   Prahalada, Srinivasa ^a,b   Berry, Peter H ^a,b   Alberts, Alfred W ^a,b   Bokelman, Delwin L ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Chibret ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ANIMAL; ANIMAL EXPERIMENT; CARCINOGENESIS; DRUG TOXICITY; EYE TOXICITY; HISTOLOGY; LIVER TOXICITY; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TERATOGENESIS;

ANIMAL; CATARACT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LOVASTATIN; NEOPLASMS, EXPERIMENTAL; RISK FACTORS;

EID: 0023733253     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(88)90003-3     Document Type: Article

References (28)

1. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth
2. Regulation of HMG-CoA reductase
3. Biochemistry of polyisoprenoid biosynthesis
4. Essential role for mevalonate synthesis in DNA replication
5. Biosynthesis of ubiquinones in animals
6. Impairment of dolichol saccharide synthesis and dolichol-mediated glycoprotein assembly in the aortic smooth muscle cell in culture by inhibition of cholesterol biosynthesis
7. Physiological disposition of lovastatin
8. Lack of correlation between the rate of cholesterol biosynthesis and the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rats and in fibroblasts treated with ML-236B
9. Effects of ML-236B on cholesterol metabolism in mice and rats lack of hypocholesterolemic activity in normal animals
10. Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers
11. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylgiutaryl-coenzyme-A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes
12. Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits
13. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. A new class of cholesterol lowering agents
14. Dose response in butylated hydroxyanisole induction of forestomach carcinogenesis in F344 rats
15. Discovery biochemistry and biology of lovastatin
16. Implications of mouse liver neoplasms for predicting carcinogenicity
17. The genotoxic/epigenetic distinction: relevance to cancer policy
18. An analysis of the carcinogenic testing experience of the National Cancer Institute
19. Epigenetic effects of liver tumor promoters and implications for health effects
20. Enhancement of spontaneous tumorigenesis in C3H mice by dietary phenobarbital
21. Dose-response relationships for phenobarbitone promotion of mouse liver tumors initiated by a single dose of dimethylnitrosamine
22. Anticonvulsant drugs and cancer
23. On the absence of carcinogenicity to man of phenobarbital. The Danish Cancer Registry, the Finsen Institute
24. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
25. Efficacy and long-term safety of lovastatin
26. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin
27. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
28. Cataracts produced by triparanol (MER/29)